Proactive Investors Interview – Algernon Pharmaceuticals Study of Ifenprodil for the Treatment of IPF and Chronic Cough Reaches Key Stage
Algernon Pharmaceuticals Study of Ifenprodil for the Treatment of IPF and Chronic Cough Reaches Key Stage Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news that Algernon has announced positive data showing the Company has met a co-primary endpoint in it’s Phase 2 proof of concept study evaluating Ifenprodil in the treatment of idiopathic pulmonary fibrosis (IPF) and chronic cough. Mr. Moreau explains to Proactive that the IPF data has shown 65% of patients had stable or improved forced vital capacity (FVC) over the 12-week treatment period with statistical significance when compared to an …
Streetwise Reports – Can the Psychedelic Drug DMT Take Algernon to the Next Level?
Can the Psychedelic Drug DMT Take Algernon to the Next Level? Can a psychedelic compound help you heal after a stroke? This biopharmaceutical company hopes it can and plans to start Phase 1 trials this September. Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGN0:XFRA)patent applications for DMT, a psychedelic compound to treat strokes include the addition of two novel salts creating two entirely new drug compounds, the company has announced. The pure or freebase form of N, N-dimethyltryptamine (DMT) occurs in nature so it can’t be patented, but the addition of nicotinate and pamoate salts slightly alters the drug’s chemical fingerprint, making …
Algernon Pharmaceuticals Provides Update on Chronic Kidney Disease Research Program with NP-251
Algernon Pharmaceuticals Provides Update on Chronic Kidney Disease Research Program with NP-251 Algernon Pharmaceuticals CEO Christopher J. Moreau joined Steve Darling from Proactive to share an update on the Company’s drug NP-251, or Repirinast, which is being investigated in the treatment of Chronic Kidney Disease (CKD). Mr. Moreau explains to Proactive that the pre-clinical animal model of kidney fibrosis showed Repirinast reduced fibrosis by 50% with statistical significance. As part of the new CKD research program, Algernon Pharmaceuticals will also investigate the use of Repirinast in acute interstitial nephritis, which causes inflammation of parts of the kidney. …
Algernon Pharmaceuticals Phase 1 DMT Stroke Study Will Start in September 2022
Proactive Investors Interview – Algernon Pharmaceuticals Phase 1 DMT Stroke Study Will Start in September of 2022 Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the Company has engaged the Centre for Human Drug Research and the pharmacy at the Leiden University Medical Center in the Netherlands to conduct its Phase 1 DMT Stroke Study which is expected to begin in September of 2022. Mr. Moreau explains how the study is being designed to investigate prolonged intravenous infusion of DMT for durations which have never been clinically studied. …
Business Television – Algernon Pharmaceuticals and the DMT/Stroke Clinical Program
Join Christopher J. Moreau, CEO of Algernon Pharmaceuticals as he discusses investigating the psychedelic drug DMT as a new potential treatment for Stroke. …
Streetwise Live! – Algernon is Awaiting Approval for a Phase 1 DMT Human Stroke Study
Listen to Cyndi Edwards, host of Streetwise Live!, speak with Algernon CEO Christopher J. Moreau, and ask two world-renowned psychedelic drug experts Professor David Nutt and Dr. Rick Strassman MD why DMT might work as a potential new stroke treatment. …
Proactive Investors Interview – Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy for DMT Intellectual Property
Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the Company has disclosed that its intellectual property patent applications, filed in early 2021 for AP-188, included novel salt forms of DMT. Mr. Moreau explains that a novel salt form of a drug is a new and separate structure from the original compound and is considered a new composition of matter. Many drug compounds’ core structures can often be paired with a salt. Different salts can improve the core drug in several ways, including improved efficacy, safety/tolerability, and stability. …
Proactive Investors Interview – Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Stroke Study
Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the Company has applied for a combined Clinical Trial and Ethics Approval application in the UK for a planned Phase 1 clinical human study of AP-188 or DMT in stroke patients. Mr. Moreau explains that the focus of this study is to investigate prolonged intravenous infusion of DMT, for durations that have never been clinically studied. This data, the company hopes, will help with its Phase 2 acute stroke and rehabilitation studies. …
This Pharmaceutical Company Has a Brilliant Concept – An Expert Opinion
Biotech is hard. It is full of failure and the frustrations of waiting, so it takes a lot for me to get excited about this sector. But I am beyond excited about one company that has found a conceptual loophole that puts its operations in a constant fast-forward or leapfrog mode, placing them heads above any other drug developers. Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW:FSE), and it remains one of only two pharmaceutical companies… View full story at: https://www.streetwisereports.com/article/2022/01/17/this-pharmaceutical-company-has-a-brilliant-concept.html …
Algernon Pharmaceuticals Ifenprodil Chronic Cough Study Receives Positive Feedback from U.S. FDA
Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news that the Company has received positive feedback from the U.S. Food and Drug Administration at their Pre-Investigational New Drug meeting regarding the use of Ifenprodil for the treatment of chronic cough. …
About Us
